Biological & Pharmaceutical Bulletin 2012-01-01

Mizoribine suppresses proliferation of rat glomerular epithelial cells in culture and inhibits increase of monocyte chemoattractant protein-1 and macrophage inflammatory protein-2 stimulated by thrombin.

Hideaki Yamabe, Michiko Shimada, Reiichi Murakami, Takeshi Fujita, Yuko Shimaya, Norio Nakamura

Index: Biol. Pharm. Bull. 35(5) , 705-8, (2012)

Full Text: HTML

Abstract

Glomerular crescents play an important role in progressive glomerular injury. The lesions consist of epithelial cells, macrophages and fibrin deposition. Macrophage chemoattractant protin-1 (MCP-1) is a chemoattractant of monocytes, which has a potential of procoagulant activity. Macrophage inflammatory protein-2 (MIP-2) is a chemoattractant of neutrophils and acute necrotizing injury is primarily mediated by neutrophils in crescentic glomerulonephritis. Mizoribine (MZR) is an immunosuppressive drug and it has been used for organ transplantation and treatment of various autoimmune diseases. The aim of this study is to investigate the effects of MZR on glomerular epithelial cells (GEC). Rat GEC were cultured with K1 medium and used from 12th to 14th passage. GEC proliferation was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. MCP-1 and MIP-2 were quantified by enzyme-linked immunosorbent assay (ELISA) in culture supernatants and mRNA expressions of MCP-1 and MIP-2 were analyzed by real-time reverse transcriptase-polymerase chain reaction (RT-PCR). The proliferation of GEC was suppressed by MZR in a dose-dependent manner in the range of 1.0-100.0 µg/mL. These concentrations of MZR had no toxic effect to GEC. Thrombin (1.0-5.0 U/mL) enhanced the production of MCP-1, MIP-2 and the mRNA expressions of MCP-1 and MIP-2. The stimulatory effect of thrombin was inhibited by addition of MZR (10 µg/mL). It is concluded that MZR may be useful for the treatment of crescentic glomerulonephritis.


Related Compounds

Related Articles:

Successful multitarget therapy using mizoribine and tacrolimus for refractory Takayasu arteritis.

2014-08-01

[Rheumatology (Oxford.) 53(8) , 1530-2, (2014)]

[Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 5. Leflunomide and mizoribine].

2011-10-10

[Nippon. Naika Gakkai Zasshi. 100(10) , 2929-35, (2011)]

Spantide II, a novel tachykinin antagonist having high potency and low histamine-releasing effect.

1990-10-29

[Clin. Transplant. 10 , 116, (1996)]

Monoclonal antibodies to lipopolysaccharide antigens of Salmonella enterica serotype Typhimurium DT104.

2011-02-01

[Hybridoma 30 , 43-52, (2011)]

Therapeutic effect of mizoribine on pemphigus vulgaris and pemphigus foliaceus.

2012-01-01

[Dermatol. Ther. 25(4) , 382-5, (2012)]

More Articles...